Marinus Pharmaceuticals. has been granted a patent for methods to treat tuberous sclerosis complex and related epilepsy. The patent specifically covers the administration of ganaxolone, a pregnenolone neurosteroid, to alleviate symptoms in affected individuals. GlobalData’s report on Marinus Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Marinus Pharmaceuticals, Nanoparticle drug conjugates was a key innovation area identified from patents. Marinus Pharmaceuticals's grant share as of June 2024 was 28%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of tuberous sclerosis-related epilepsy using ganaxolone
The granted patent US11980625B2 outlines a method for treating tuberous sclerosis-related epilepsy through the administration of ganaxolone, a therapeutic agent. The claims specify that the treatment involves administering a therapeutically effective amount of ganaxolone to individuals diagnosed with this condition. Various administration routes are detailed, including oral forms such as suspensions, capsules, and tablets, as well as intravenous infusion. The claims emphasize the importance of achieving a plasma concentration of ganaxolone of at least 100 ng/ml for a significant portion of the day, specifically at least 70%.
Further specifications in the claims delineate the dosage parameters, indicating that the effective daily amount of ganaxolone should not exceed 1800 mg, with preferred regimens suggesting 600 mg or 500 mg administered three times daily. Additionally, the claims provide alternative dosage limits, including a maximum of 1500 mg per day and a weight-based dosage of 63 mg/kg per day, with a recommended regimen of 21 mg/kg three times daily. This patent thus establishes a comprehensive framework for the therapeutic use of ganaxolone in managing epilepsy associated with tuberous sclerosis, detailing both the administration methods and dosage guidelines.
To know more about GlobalData’s detailed insights on Marinus Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
